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Objectives: The aim of the study was to evaluate the outcomes of retrograde versus
antegrade approach in chronic total occlusion (CTO) percutaneous coronary interven-
tion (PCI).
Background: The retrograde approach has increased the success rate of CTO PCI but
has been associated with a higher risk for complications.
Methods: We conducted a meta-analysis of studies published between 2000 and
August 2019 comparing the in-hospital and long-term outcomes with retrograde ver-
sus antegrade CTO PCI.
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Results: Twelve observational studies (10,240 patients) met our inclusion criteria (ret-
rograde approach 2,789 patients, antegrade approach 7,451 patients). Lesions treated
with the retrograde approach had higher J-CTO score (2.8 vs. 1.9, p < .001). Retro-
grade CTO PCI was associated with a lower success rate (80.9% vs. 87.4%, p < .001).
Both approaches had similar in-hospital mortality, urgent revascularization, and cere-
brovascular events. Retrograde CTO PCI was associated with higher risk of in-
hospital myocardial infarction (MI; odds ratio [OR] 2.37, 95% confidence intervals
[CI] 1.7, 3.32, p < .001), urgent pericardiocentesis (OR 2.53, 95% CI 1.41–4.51,
p = .002), and contrast-induced nephropathy (OR 2.12, 95% CI 1.47–3.08; p < .001).
During a mean follow-up of 48 ± 31 months retrograde crossing had similar mortality
(OR 1.79, 95% CI 0.84–3.81, p = .13), but a higher incidence of MI (OR 2.07, 95% CI
1.1–3.88, p = .02), target vessel revascularization (OR 1.92, 95% CI 1.49–2.46,
p < .001), and target lesion revascularization (OR 2.08, 95% CI 1.33–3.28, p = .001).
Conclusions: Compared with antegrade CTO PCI, retrograde CTO PCI is performed
in more complex lesions and is associated with a higher risk for acute and long-term
adverse events.
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1 | INTRODUCTION
Coronary chronic total occlusion (CTO) percutaneous coronary inter-
ventions (PCI) can be challenging with failure to cross being the main
cause of failure. The introduction of retrograde CTO crossing tech-
niques was instrumental in increasing CTO PCI success rates from
<70%1,2 to nearly 90%.3–5 Some, but not all,6,7 studies have reported
that the retrograde approach is associated with longer procedural
time, increased use of contrast and fluoroscopy, and higher incidence
of periprocedural and possibly long-term adverse cardiac events.4,8–17
We performed a systematic review and a meta-analysis of in-hospital
and long-term outcomes with retrograde as compared with antegrade
CTO PCI.
2 | METHODS
2.1 | Literature search
The current meta-analysis was conducted and reported according
to the proposal for conducting and reporting Meta-analyses of
observational studies (MOOSE)18 and is registered with the Inter-
national Prospective Register for Systematic Reviews (PROSPERO:
CRD42019124763). We performed a systematic computerized sea-
rch of the EMBASE, Cochrane, and MEDLINE databases from 2000
to August 2019 using the following search terms separately and in
combination; “chronic total occlusion,” “CTO,” “CTO PCI,”
“retrograde,” “antegrade,” and “revascularization.” We screened the
bibliographies of the retrieved studies for relevant studies not
retrieved through the initial search. Our search was limited to the
English language. Abstracts and review papers were not included in
this study.
2.2 | Study selection
We included published studies that compared the outcomes with ret-
rograde versus antegrade approaches in CTO PCI. If more than one
study reported outcomes of the same cohort of patients, we included
the most recent or most comprehensive publication. For long-term
outcomes, we included studies with a minimum of 12 months
follow-up.
2.3 | Data extraction and quality assessment
The data were abstracted by two independent investigators (AA, MS)
and adjudicated by a third investigator (MM); all the investigators are
physicians. Discrepancies were settled by consensus. The risk of bias
of the included studies was assessed using the Newcastle-Ottawa
Scale for observational studies.19
2.4 | Study end-points
Primary endpoints were in-hospital mortality, myocardial infarction
(MI), need for urgent revascularization, need for urgent peri-
cardiocentesis, contrast-induced nephropathy, procedural success,
procedural time, fluoroscopy time, and contrast volume. Secondary
endpoints included long-term outcomes: all-cause mortality, MI, target
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lesion revascularization (TLR), and target vessel revascularization
(TVR). The definitions of outcomes, according to each included study
are described in Table S1. Long-term outcomes were reported at the
longest follow-up time available. For this analysis, the total number of
lesions was utilized for procedural success while the total number of
patients was used for clinical outcomes. One study reported baseline
characteristics and outcomes according to the total number of lesions,
and this number was used for our analysis.12 Lesion complexity was
reported using the J-CTO score.20
2.5 | Data synthesis and statistical analysis
Statistical analysis was conducted using the Review Manager Soft-
ware (Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, the
Cochrane Collaboration, 2014). Categorical variables were described
as percentages while continuous variables were described as means
with SD. Categorical variables were compared using Fisher's exact
test or chi-square test, while continuous variables were compared
using the two-sample t test. Tests were two-tailed, and a p value ≤.05
was considered statistically significant.
Odds ratios (ORs), and mean difference (MD) with 95% confi-
dence intervals (CIs) are presented as summary statistics. CIs were cal-
culated at 95% level for overall estimates effect. Statistical
heterogeneity was assessed by I2 statistics; I2 statistic >50% was con-
sidered substantial, and I2 > 75% was considered considerable.21 As a
high degree of clinical and methodological heterogeneity was antici-
pated, we used the Der-Simonian and Laird random-effects and
random-effects generic inverse variance methods to calculate OR and
MD, respectively.22 Baseline characteristics, follow-up periods, and
event rates were weighted according to sample size. Potential publica-
tion bias was assessed using the Egger's test through visual examina-
tion of the funnel plots.23
A subgroup test for statistical interaction was performed to
assess whether the association between retrograde (vs. antegrade)
procedures and outcomes differed when retrograde was used as a
primary strategy (retrograde approach was the primary approach
used in >95% of the patients) versus only after failure of the
antegrade approach. Sensitivity analysis was performed excluding
lower quality studies as assessed by the Newcastle–Ottawa
Scale.10
3 | RESULTS
3.1 | Characteristics of the included studies and
quality assessment
The study selection process is described in Figure S1. Twelve observa-
tional studies with a total of 10,240 patients (10,363 lesions) met our
inclusion criteria.4,8,10–17,24,25 The characteristics of the included stud-
ies are described in Table 1. Patients were enrolled from 2005 to
2016. Three studies reported patients from North America,4,8,11 four
from Europe,10,12,16,17 and five from Asia.13–15,24,25 The retrograde
approach was used as the primary approach in two studies17,24; after
the failure of antegrade approach in two studies10,16; and as a mix of
both in the rest of the studies.4,8,11–15,25 The retrograde arm included
2,789 patients (2,816 lesions), while the antegrade arm included
7,451 patients (7,547 lesions).
Long-term outcomes were reported in four studies, including
2,269 patients who completed follow-up.8,13,15,17 The weighted mean
follow-up duration was 48 ± 31 months. All studies met the inclusion
criteria. Publication bias, as assessed by the Egger's test funnel plots is
illustrated in Figures S2–S11. Bias assessment as per the Newcastle–
Ottawa Scale for observational studies is shown in Table S2.
3.2 | Baseline characteristics of the included cohort
The baseline clinical and angiographic characteristics for lesions and
patients undergoing CTO PCI using the retrograde versus an









approach (primary or after
antegrade approach failure)
Galassi et al. 2011 Observational Europe, 16 2008–2009 1983/1983 97.2% primary
Michael et al. 2014 Observational USA, 1 2008–2011 193/193 34% primary
Werner et al. 2014 Observational Germany, 1 2006–2011 392/492 After failure of antegrade
Bijuklic et al. 2016 Observational Germany, 1 2008–2012 369/369 After failure of antegrade
Dautov et al. 2016 Observational Canada, 1 2010–2015 175/175 Both
Karmpaliotis et al. 2016 Observational USA, 11 2012–2015 1276/1301 46% primary
Lee et al. 2017 Observational Taiwan,1 2012–2013 321/321 40.2% primary
Suzuki et al. 2017 Observational Japan, multi-center 2014–2015 2596/2596 100% primary
Zivelonghi et al. 2018 Observational Belgium & Netherlands, 8 2012–2015 330/330 100% primary
Tanaka et al. 2018 Observational Japan, 1 2005–2009 842/928 Not reported
Kwon et al. 2018 Observational Korea,1 2007–2015 1151/1151 58% primary
Wu et al. 2019 Observational Asian pacific registry 2016 485/497 65% primary
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antegrade-only approach are summarized in Table S3. Patients in the
retrograde arm had more prior MIs (43% vs. 35.2%, p < .001), prior
PCIs (69.7% vs. 41.7%, p < .001), and prior failed attempts (43.7%
vs. 19.9%, p < .001). Lesions treated with the retrograde approach
were more likely to be in the right coronary artery (RCA) (62.8%
vs. 47.3%, p < .001), were longer (35.2 ± 13.6 vs. 21.9 ± 9 mm,
p < .001) and had higher mean J-CTO score (2.8 ± 1.2 vs. 1.9
± 1.2, p < .001).
3.3 | Study endpoints
3.3.1 | In-hospital adverse events
The retrograde and antegrade-only CTO PCI had similar in-hospital
mortality (0.5% vs. 0.21%; OR 2.01, 95% CI 0.91–4.43; p = .08,
I2 = 0%). Use of the retrograde approach was associated with higher
incidence of MI (3.07% vs. 1.27%; OR 2.37, 95% CI 1.7–3.32,
p < .001; I2 = 0%), need for urgent pericardiocentesis (1.07%
vs. 0.42%; OR 2.53, 95% CI 1.41–4.51, p = .002, I2 = 0%), and
contrast-induced nephropathy (3.38% vs. 1.57%; OR 2.12, 95% CI
1.47–3.08; p < .001, I2 = 0%). There was no difference in the need for
urgent revascularization (0.21% vs. 0.34%; OR 0.82, 95% CI
0.30–2.25, p = .70; I2 = 0%) or cerebrovascular events (0.44%
vs. 0.19%; OR 1.95, 95% CI 0.87–4.38; p = .11, I2 = 0%) (Figures S12
and S13).
3.3.2 | Procedural characteristics
Compared with antegrade CTO PCI, retrograde CTO PCI was associ-
ated with lower procedure success rate (80.9% vs. 87.4%; OR for pro-
cedural failure 2.16, 95% CI 1.71–2.73, p < .001, I2 = 63%), longer
duration (mean difference 61.52 min, 95% CI 50.57–72.48 min),
p < .001, I2 = 97%), longer fluoroscopy time (mean difference
32.33 min, 95% CI 23.45–41.22 min; p < .001, I2 = 99%), and higher
contrast volume (mean difference 76.73 mL; 95% CI 50.9–96.55 mL,
p < .001, I2 = 95%), (Figure S14).
3.3.3 | Long-term outcomes
During a mean follow-up duration of 48 ± 31 months, there was no
difference in long-term mortality with retrograde versus antegrade
procedures (13% vs. 8.8%; OR 1.79, 95% CI 0.84–3.81, p = .13,
I2 = 74%). The retrograde approach, however, was associated with
higher risk of MI (5.6% vs. 2.6%; OR 2.07, 95% CI: 1.10–3.88, p = .02,
I2 = 0%), TVR (32.3% vs. 17.3%; OR 1.92, 95% CI: 1.49–2.46,
p < .001, I2 = 0%), and TLR (12.9% vs. 7.2%; OR 2.08, 95% CI:
1.33–3.25, p = .001, I2 = 0%; Figure S15).
3.4 | Subgroup and sensitivity analyses
On subgroup analysis, the association between retrograde PCI and
outcomes was not significantly different based on whether retrograde
was performed as the primary approach versus after a failed
antegrade crossing attempt: in-hospital mortality (p interaction = .28),
procedural success (p interaction = .68), or the need for urgent peri-
cardiocentesis (p interaction = .30; p interaction = .28); Figure S16).
With the exclusion of one lower quality study,10 there was no differ-
ence in the outcomes after both approaches.
The summary of the study results is illustrated in Figure 1.
4 | DISCUSSION
To the best of our knowledge, this is the first meta-analysis of both
in-hospital and long-term outcomes with retrograde versus
antegrade-only crossing techniques in CTO PCI. The main findings can
be summarized as follows: (a) patients who underwent retrograde CTO
PCI had more technically complex lesions, a higher prevalence of prior
PCI and CABG, and more comorbidities; as a result, the retrograde pro-
cedures were longer requiring more contrast and fluoroscopy; (b) the
retrograde approach was associated with higher in-hospital MI, urgent
pericardiocentesis, and contrast-induced nephropathy compared with
the antegrade approach, but no difference in in-hospital mortality,
urgent revascularization, or cerebrovascular events; and (c) the retro-
grade approach was associated with higher long-term incidence of MI,
TLR, and TVR but not mortality.
Several observational studies26–31 and two RCTs32,33 have
reported that successful CTO PCI is associated with improvement in
the quality of life, reduced need for CABG, improved left ventricular
(LV) function, and LV reverse remodeling compared with failed revas-
cularization. The retrograde approach is currently an essential tool for
achieving high success rates, especially in complex lesions where the
antegrade approach is not technically feasible or fails.34 According to
the hybrid algorithm, proximal cap ambiguity, poor-quality distal ves-
sel and the presence of interventional collaterals favor the use of the
retrograde approach.35 In a multicenter CTO PCI registry, overall tech-
nical success was 86%, and the retrograde approach was used in
34.9% of the successful cases.5 The higher success rate with the ret-
rograde approach is likely related to the histopathological features of
the distal CTO cap which is more likely to be tapered and less fibro-
calcific and therefore less resistant to guidewire advancement.36,37
In our analysis, the retrograde procedures were longer requiring more
contrast and fluoroscopy and were associated with more in-hospital
adverse events. Coronary perforation (Ellis classification grade III) with
subsequent need for pericardiocentesis has been associated with high
rates of long-term major adverse cardiac events.38 Peri-procedural MI,
which is more likely to occur with the retrograde approach, likely due to
the prolonged obstruction of collateral channels by the retrograde wire
and microcatheters, has also been associated with worse long-term out-
comes and higher mortality in some but not all studies.16,39,40 Most of
these CTOs, however, could not have been revascularized by an
antegrade-only approach and some of the complications attributed to the
retrograde approach may have occurred during antegrade crossing
attempts. Moreover, some studies in our analysis included patients from
2005, which was early in the learning curve of the retrograde technique.
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Similar to previous reports7,41 in our study retrograde CTO PCI
was associated with more TLR, TVR, and MI as compared with
antegrade-only CTO PCI during a mean follow-up of 4 years. Retro-
grade PCI is usually performed in more complex anatomy and might
lead to implantation of longer and smaller-caliber stents, which in turn
is associated with a higher risk of restenosis.42 Moreover, dis-
section and re-entry techniques, which are frequently used in the ret-
rograde approach, may increase restenosis rates.43,44
The majority of patients in the retrograde group might have failed
revascularization leading to subsequent worse outcomes, and a higher
number of lesions in the retrograde group had already failed prior
attempts rendering the retrograde approach the final option for suc-
cessful revascularization. It possible that the worse outcomes with the
retrograde approach are related to higher patient and lesion complex-
ity and not the crossing strategy per se. Nevertheless, the retrograde
approach should only be used when the perceived benefits outweigh
the potential risks. Performance of retrograde CTO PCI by experi-
enced operators who can identify and treat complications early and
are attentive to the need for stent optimization,45 as well as using
approaches that help reduce complications like the radial approach,46
could improve the outcomes of retrograde CTO PCI.
4.1 | Limitations
Our study has limitations. First, only observational studies compared
antegrade and retrograde CTO PCIs, which are subject to selection
bias. Second, there was a high degree of heterogeneity between the
studies (e.g., in the definition of success and periprocedural MI). Third,
the details of the crossing techniques and the collaterals used for ret-
rograde approach were not consistently reported in all studies and
could not be used for further analysis. Fourth, the differential out-
comes based on J-CTO components (e.g., calcification, occlusion
length) were not consistently reported and, therefore, could not be
reported. Finally, the included studies did not report the adjusted odds
ratios. Thus, despite being the optimal statistical method, we could
not use the pooled adjusted OR to confirm our results.
5 | CONCLUSION
Compared with antegrade CTO PCI, the retrograde approach is
attempted in more complex lesions and is associated with a higher risk
for acute and long-term complications. Judicious and skillful applica-
tion of the retrograde approach remains a pillar of contemporary
CTO PCI.
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